Key Takeaways
- A bottoming year, with a steep FY25 ramp promised: FY24 revenue guided to just 5–7% growth, but management expects 70–100% revenue growth in FY25, driven by new product commercializations and a demand recovery that has not yet materialized.
- PTC segment is the epicenter of pain: Order postponements, not cancellations, are concentrated here, with domestic volumes and margins eroded by Chinese competition; exports remain healthier with new CY24 contracts being built.
- SDA poised for a breakout on new customer wins: A newly approved large global customer, won on a non-Chinese supply chain solution, is expected to begin commercialization from February 2024, with management targeting 80–100% segment growth in FY25.
- Margins normalized as old inventory cleared: Gross margin improved to 61% as high-cost inventory was largely consumed, but employee costs spiked to 15% of revenue on new facility staffing; overhead absorption is expected to improve with volumes.
- What to watch next quarter: Whether the Q4 "handsome quarter" materializes, the pace of SDA volume ramp from the new customer, and any stabilization in PTC demand.
Demand Environment & Segment Performance
- Industry still in de-stocking: The chemical industry faces low demand from ongoing de-inventorying, and anticipated product price increases were short-lived due to low-cost Chinese products flooding the market.
- PTC segment hit hardest: All product postponements are in PTC, with no cancellations but deliveries pushed out, incurring storage and demurrage costs on containers already at foreign ports. Domestic PTC is highly price-sensitive, with significant volume and margin erosion from Chinese and local competition. Export PTC remains in good shape with established contracts and new CY24 contracts being built.
- SDA market gradually recovering: Commercial vehicle sales are improving steadily except in China. De-inventorying by catalyst producers kept demand lower. Of three large customers, one provides most current volumes, a second is at near-zero and not expected to resume until at least February, and a third has returned with smaller orders. A fourth newly added customer is growing steadily.
- Pharma and Agro intermediates resilient: Most business continued without significant impact. Two pharmaceutical intermediates were delivered from plant scale for final validation, and one Agro intermediate was delivered for plant-scale approval. A large potential Agro intermediate's validation was postponed to January 2024 due to the customer's extended plant shutdown.
- Flame retardants still on hold: Manufacturing remains suspended due to market conditions, though the new Middle East geopolitical situation may change things positively. A formal approval from an important western hemisphere customer was received after nearly 15 months.
- Electrolyte salts in a lull: An existing large customer completed plant debottlenecking and resumed procurement slowly while consuming piled-up inventory. Another large potential customer's project is moving toward commercialization, with FY25 seen as the key turning point for exponential growth over three years.
Chintan Shah: "the chemical industry is definitely going through a never seen before situation and the pain is yet not completely over"
SDA: The Growth Engine for FY25
- New large customer win: Formal approval received 3–4 days before the call from one of the largest potential SDA customers globally. The win came from providing a non-Chinese origin supply chain solution for an existing product the customer buys from competitors. Significant contribution is expected from next financial year.
- Commercialization timeline: First commercialization for the new customer begins February 2024, with ramp-up potentially from July 2024 onward. Volumes from the existing large customer are also expected to rise significantly from April 2024 as its approval nears completion.
- Segment growth target: Management expects at least 80% to 100% growth in SDA in terms of value for FY25, with volumes rising significantly from April 2024.
- Existing customer dynamics: Currently, most SDA volumes come from only one single customer plus the newly added fourth customer. The second customer continues at almost zero volumes, and the third has returned with smaller orders. The market is not back to normal but is gradually moving in that direction.
Chintan Shah: "We expect at least 80% to 100% growth in this segment in terms of value."
New Product Pipeline & Commercialization
- Six intermediates nearing commercialization: Three pharmaceutical intermediates and three agro intermediates are in final stages. All three agro products are expected to commercialize between April and June of next year, with one ready to supply in January for final qualification and a third awaiting special equipment expected by November.
- Revenue potential from new products: From existing revenue, management expects nearly 200% growth at least from these six new product introductions, with potential to reach 300–350% growth at high volumes. FY25 is expected to capture 30–40% of full potential as a learning curve, with FY26 reaching fuller potential.
- Pharma intermediates timeline: Commercialization of three pharmaceutical intermediates is expected by early 2025.
- Agro intermediate delay: One large product's commercialization was postponed by one quarter to May or June next year because the customer's plant shutdown extended from 2 weeks to 6 weeks, and the customer does not want delivery before December due to inventory concerns.
- Other pipeline progress: Rare-earth chemical extraction products were supplied during the quarter, awaiting customer's customer approval. Monoglyme continuous flow piloting is running successfully, and plant-scale equipment design has begun, with production expected in the next 12 months. Two products are already waiting in queue for the pilot equipment.
Margins, Costs & Balance Sheet
- Gross margin improved to 61%: Only Rs. 5–6 crores of old high-cost inventory was consumed; most inventory was bought in the last 4–5 months at significantly lower prices, while finished goods sold at almost the same price levels. A favorable product mix also helped, with three high-margin products seeing significantly higher volumes.
- Old inventory overhang: Management expects to absorb a loss of about Rs. 7–8 crores from remaining old inventory, which may hit in one quarter or spread over three quarters since some of these products have not been produced in the last 3–4 months.
- Employee cost spike: Employee expenses rose 44% and reached 15% of revenue (vs. a normal 6–8%) due to new facility staffing and validation production running. This is expected to normalize next financial year when volumes hit.
- Power and fuel cost up 50%: The Dahej SEZ facility moved to natural gas, which is slightly more expensive but environmentally cleaner.
- Finance cost to decline: Finance cost increased 72% during the quarter but will substantially decline going forward due to reduction in working capital utilization from QIP proceeds.
- Overhead absorption ahead: With anticipated increase in business volumes over the next couple of quarters, overheads will start getting absorbed uniformly, translating into better and more realistic margins.
- Tax rate: Effective tax rate is likely around 29–30% this year due to deferred tax liability from Rs. 250 crores of CAPEX. The Dahej plant has a 50% tax rate for five years and is currently in its second year; once depreciation is consumed, lower taxation provisions will apply, potentially in FY25.
Chintan Shah: "Honestly, I don't consider R&D expenses as an expense because without this, we are not going to grow ever. So, I would not say this is an expense. I would say this is practically an investment that we are making."
Strategic Initiatives
- Non-Chinese supply chain: The company successfully indigenized production of certain key raw materials previously dependent on imports, supplied product on plant scale, and is now under final stages of qualification. This gives customers an independent-of-China supply chain option, a concept that directly won the new large SDA customer.
- Ultra high purity chemicals: Development work on ultra high purity chemicals for electronic applications is progressing steadily.
- Capacity debottlenecking: Rs. 30–40 crores of expenses are planned for debottlenecking over the next 6–8 months. Once completed, the new facility will be ready to support 100% growth.
Chintan Shah: "This is coming because of adopting the concept of providing them a solution to have a security of supply by having a non-Chinese origin supply chain. This concept has paid off."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY24 revenue growth | Nearly flattish, maybe 5% to 7% growth | FY24 |
| FY24 EBITDA | Close to about Rs. 100 crores | FY24 |
| FY25 revenue growth | At least 70% to 100% growth | FY25 |
| SDA segment growth | At least 80% to 100% growth in value | FY25 |
| New SDA customer commercialization | First volumes begin February 2024, ramp from July 2024 | Q4FY24 onward |
| Three agro intermediate commercializations | All three between April and June of next year | Q1FY26 |
| Three pharma intermediate commercializations | By early 2025 | Early CY2025 |
| Flame retardant production restart | Slow commercial production begins for newly approved customer | Q4FY24 |
| Old inventory loss absorption | Rs. 7–8 crores loss, in one quarter or spread over three | Over next 1–3 quarters |
| Capacity debottlenecking | Rs. 30–40 crores of expenses | Next 6–8 months |
| Monoglyme plant-scale production | Begin within next 12 months | ~Q3FY25 |
| Tax rate reduction | Drastically down from 29–30% as depreciation is consumed | Potentially FY25 |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue from operations | ₹96.7 cr, +7% YoY |
| EBITDA | ₹20.2 cr, +81% YoY |
| EBITDA margin | 20.9%, up 849 bps YoY from 12.4% |
| PAT | ₹7.8 cr, +9% YoY |
| PAT margin | 8.05%, vs 7.89% in Q2 FY23 |
| Gross profit margin | 61%, up sharply from ~50% range historically |
| FY24 revenue growth guidance | 5% to 7%, nearly flattish growth |
| FY24 EBITDA guidance | ~₹100 cr |
| FY25 revenue growth guidance | 70% to 100% |
| SDA quarterly revenue | ₹42.8 cr, +487% YoY |
| PTC quarterly revenue | ₹23.2 cr, -25% YoY |
| Pharma and Agro Intermediates and Specialty Chemicals quarterly revenue | ₹28.8 cr, -22% YoY |
| Electrolyte Salts quarterly revenue | ₹1.2 cr, -79% YoY |
| Exports | ₹67.1 cr, 69% of revenue from operations |
| Employee cost as % of revenue | ~15%, vs normal 6% to 8% |
| Headcount increase in H1 FY24 | 116 |
| Effective tax rate guidance FY24 | 29% to 30% |
| CAPEX FY24 | ~₹250 cr |
| QIP proceeds utilized | ₹184 cr of ₹200 cr, 95% utilized |
| IPO proceeds utilized | ₹202.7 cr of ₹207.28 cr, 98% utilized |